The clinical pharmacology of antineoplastic agents (second of two parts).
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001374:Azacitidine / Q000378:metabolism / Q000494:pharmacology; D001761:Bleomycin / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D002330:Carmustine / Q000494:pharmacology; D002467:Cell Nucleus / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D003510:Cyclohexanes / Q000031:analogs & derivatives / Q000494:pharmacology; D003520:Cyclophosphamide / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D003561:Cytarabine / Q000378:metabolism / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000378:metabolism; D004317:Doxorubicin / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000378:metabolism; D009607:Nitrosourea Compounds / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D004273:DNA, Neoplasm; D009607:Nitrosourea Compounds; D003561:Cytarabine; D001761:Bleomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D001374:Azacitidine; D002330:Carmustine